Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,392,277
  • Shares Outstanding, K 115,830
  • Annual Sales, $ 57,880 K
  • Annual Income, $ -519,020 K
  • EBIT $ -479 M
  • EBITDA $ -468 M
  • 60-Month Beta 2.05
  • Price/Sales 21.91
  • Price/Cash Flow N/A
  • Price/Book 1.64

Options Overview Details

View History
  • Implied Volatility 98.62% (-4.08%)
  • Historical Volatility 58.51%
  • IV Percentile 84%
  • IV Rank 36.25%
  • IV High 154.61% on 10/27/25
  • IV Low 66.78% on 01/21/25
  • Expected Move (DTE 1) 0.71 (5.87%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 6,441
  • Volume Avg (30-Day) 3,445
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 132,192
  • Open Int (30-Day) 120,961
  • Expected Range 11.31 to 12.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.99
  • Number of Estimates 10
  • High Estimate -0.89
  • Low Estimate -1.10
  • Prior Year -1.24
  • Growth Rate Est. (year over year) +20.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.74 +38.67%
on 12/18/25
12.34 -1.78%
on 01/14/26
+2.98 (+32.60%)
since 12/15/25
3-Month
7.95 +52.45%
on 11/21/25
28.25 -57.10%
on 10/20/25
-13.81 (-53.26%)
since 10/15/25
52-Week
5.90 +105.42%
on 04/07/25
28.25 -57.10%
on 10/20/25
+2.41 (+24.82%)
since 01/15/25

Most Recent Stories

More News
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies,...

NTLA : 12.12 (+0.83%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies,...

NTLA : 12.12 (+0.83%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies,...

NTLA : 12.12 (+0.83%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END

AVAI : 0.6888 (+13.57%)
ANVS : 3.17 (unch)
RXRX : 4.82 (-0.62%)
ZYME : 24.51 (-0.45%)
NTLA : 12.12 (+0.83%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

MarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased...

AVAI : 0.6888 (+13.57%)
ANVS : 3.17 (unch)
RXRX : 4.82 (-0.62%)
ZYME : 24.51 (-0.45%)
NTLA : 12.12 (+0.83%)
Should You Buy the Dip in Intellia Therapeutics Stock?

A patient’s death shook Intellia Therapeutics and sank its stock. Should investors buy the dip or steer clear?

SRPT : 22.56 (-1.05%)
REGN : 754.14 (-0.63%)
PFE : 25.47 (-0.43%)
NTLA : 12.12 (+0.83%)
Is This Beaten-Down Cathie Wood Stock Still a Buy?

Intellia’s shares plunged 23% after its Q3 results showed a pipeline setback. Nonetheless, Cathie Wood’s stake in the company is expanding.

NTLA : 12.12 (+0.83%)
ARKK : 83.50 (+0.36%)
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up Consistent trend in disease stability or improvement in multiple measures...

NTLA : 12.12 (+0.83%)
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Deep, stable and durable reductions in kallikrein observed  Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free...

NTLA : 12.12 (+0.83%)
Stocks Recover on Government Reopening Hopes

The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.16%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.28%. December E-mini...

SOLV : 80.05 (+0.02%)
AMAT : 326.01 (+7.99%)
ADI : 303.43 (+1.83%)
EXPE : 291.46 (+0.24%)
AKAM : 90.07 (-0.64%)
$IUXX : 25,465.94 (-1.07%)
ZNH26 : 112-085 (-0.18%)
ESH26 : 7,002.25 (+0.52%)
QCOM : 167.19 (+1.61%)
AMD : 230.59 (+3.13%)
LRCX : 226.00 (+8.24%)
OLED : 119.99 (-3.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 13.03
2nd Resistance Point 12.69
1st Resistance Point 12.35
Last Price 12.12
1st Support Level 11.67
2nd Support Level 11.33
3rd Support Level 10.99

See More

52-Week High 28.25
Fibonacci 61.8% 19.71
Fibonacci 50% 17.08
Fibonacci 38.2% 14.44
Last Price 12.12
52-Week Low 5.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar